Konduskar Laboratories Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 19-12-2024
- Paid Up Capital ₹ 5.00 Cr
as on 19-12-2024
- Company Age 18 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 15.00 Cr
as on 19-12-2024
- Revenue 4524.46%
(FY 2017)
- Profit -136989.85%
(FY 2017)
- Ebitda -4726.36%
(FY 2017)
- Net Worth -415.24%
(FY 2017)
- Total Assets -83.46%
(FY 2017)
About Konduskar Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.00 Cr.
The company has closed loans amounting to ₹15.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Supriya Konduskar and Abhijeet Konduskar serve as directors at the Company.
- CIN/LLPIN
U24296PN2006PTC128751
- Company No.
128751
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jul 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Kolhapur, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Konduskar Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhijeet Konduskar  | Director | 13-Jul-2006 | Current |
| Supriya Konduskar | Director | 16-Feb-2018 | Current |
Financial Performance of Konduskar Laboratories.
Konduskar Laboratories Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 4524.46% increase. The company also saw a substantial fall in profitability, with a 136989.85% decrease in profit. The company's net worth observed a substantial decline by a decrease of 415.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Konduskar Laboratories?
In 2017, Konduskar Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kamud Drugs Pvt LtdActive 36 years 3 monthsSupriya Konduskar and Abhijeet Konduskar are mutual person
Konduskar Sugars Private LimitedActive 13 years 11 monthsSupriya Konduskar and Abhijeet Konduskar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 29 Jan 2009 | ₹15.00 Cr | Satisfied |
How Many Employees Work at Konduskar Laboratories?
Unlock and access historical data on people associated with Konduskar Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Konduskar Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Konduskar Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
